Global Industry Analysts, Inc., April 2010, Pages: 615
Unmet Need, and Challenges Abound II-1
Recommencement of Discontinued Trials Provides a Ray a Hope! II-2
Cancer Vaccines: Potentially a Future Aid for Melanoma Treatment II-2
How Does Cancer Vaccines
Global Industry Analysts, Inc., Oct 2011, Pages: 897
Stage as of 2010 (includes corresponding
Graph/Chart) 55
Renal Cancer 55
Select FDA-Approved Renal Cell Carcinoma Drugs 55
Skin Cancer 55
Table 16: Skin Cancer/Melanoma Drug Pipeline: Number
Datamonitor, Dec 2009, Pages: 174
cancer vaccines pipeline
A disproportionately high number of therapeutic cancer vaccines are in development for melanoma
Comparative forecasts
Datamonitor forecasts the late-phase therapeutic cancer
Global Industry Analysts, Inc., Oct 2010, Pages: 659
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening.
The report
Global Industry Analysts, Inc., Oct 2006, Pages: 387
, Breast Cancer, and Malignant Melanoma (includes
corresponding Graph/Chart) II-8
An Insight into Colorectal Cancer Therapeutic Alternatives II-9
2. Market Pulse II-10
Is Huge Cost of Drugs a Major
Global Industry Analysts, Inc., July 2009, Pages: 558
- Renal Cell
Carcinoma, Hepato Cellular Carcinoma, Melanoma, and Non-small
Cell Lung Cancer (includes corresponding Graph/Chart) II-19
Table 14: Global Sales of Nexavar
Datamonitor, April 2010, Pages: 243
rewards has driven considerable pipeline activity for small molecule targeted therapies within cancer.
Scope
-Examination of the small molecule targeted cancer therapies pipeline with in-depth clinical
MP Advisors, Jan 2011, Pages: 391
to report clinical data in 2011
- Our view on Ph III data on its BRAF inhibitor- RG7204 in first line metastatic melanoma
- Changing landscape of first line metastatic breast cancer
- Dalcetrapib
Global Industry Analysts, Inc., Oct 2008, Pages: 527
MAb Immunotherapy – Effective for Residual Ovarian Cancer II-31
Melanoma II-31
Immunologic Effector Functions
Decision Resources, Inc., July 2005, Pages: 107
legislation sets prevalence criteria that determine which indications are appropriate for orphan drug development. Indications with rapidly expanding prevalence, such as malignant melanoma and bladder cancer
IMS Health, Oct 2009, Pages: 128
that will drive and constraint this niche area Preface
Executive Summary
1. Introduction to Biologics
1.1 Scope Of the Report
1.2 Ims Biologics Definition
1.2.1 Characteristics Of Biologic Products
1
Espicom Business Intelligence Ltd, April 2007, Pages: 106
to be an effective medicine puts antibodies, and the companies having a hand in their development, into a position to create new markets. Buoyed by ticilimumab and ipilimumab, the treatment of melanoma will be among
Global Industry Analysts, Inc., Feb 2011, Pages: 416
including many key and niche players such as Bayer HealthCare AG, Biogenesis-Bago, Boehringer Ingelheim GmbH, Heska Corporation, Imugene Limited, Indian Immunologicals Ltd., Lohmann Animal Health, Merck & Co
Bioseeker, Jan 2005, Pages: 174
for treating patients brain metastases. In turn, Orphan Drug Status was granted to BAY 43-9006 for renal cancer, PI-88 for melanoma and Revlimid for myelodysplastic syndromes. Four FDA approvals were also
